TY - JOUR
T1 - Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis
T2 - An international observational study
AU - Bain, Robert
AU - Cosgriff, Rebecca
AU - Zampoli, Marco
AU - Elbert, Alexander
AU - Burgel, Pierre Régis
AU - Carr, Siobhán B.
AU - Castaños, Claudio
AU - Colombo, Carla
AU - Corvol, Harriet
AU - Faro, Albert
AU - Goss, Christopher H.
AU - Gutierrez, Hector
AU - Jung, Andreas
AU - Kashirskaya, Nataliya
AU - Marshall, Bruce C.
AU - Melo, Joel
AU - Mondejar-Lopez, Pedro
AU - de Monestrol, Isabelle
AU - Naehrlich, Lutz
AU - Padoan, Rita
AU - Pastor-Vivero, Maria Dolores
AU - Rizvi, Samar
AU - Salvatore, Marco
AU - Filho, Luiz Vicente Ribeiro Ferreira da Silva
AU - Brownlee, Keith G.
AU - Haq, Iram J.
AU - Brodlie, Malcolm
N1 - Publisher Copyright:
© 2020
PY - 2021/1
Y1 - 2021/1
N2 - Background: The presence of co-morbidities, including underlying respiratory problems, has been identified as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infection in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with CF, their families, caregivers and clinical teams. Methods: Cases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020. Results: Data on 105 children were collated and analysed. Median age of cases was ten years (interquartile range 6–15), 54% were male and median percentage predicted forced expiratory volume in one second was 94% (interquartile range 79–104). The majority (71%) of children were managed in the community during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antiviral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had lower lung function and reduced body mass index Z-scores. One child died six weeks after testing positive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease. Conclusions: SARS-CoV-2 infection in children with CF is usually associated with a mild illness in those who do not have pre-existing severe lung disease.
AB - Background: The presence of co-morbidities, including underlying respiratory problems, has been identified as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infection in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with CF, their families, caregivers and clinical teams. Methods: Cases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020. Results: Data on 105 children were collated and analysed. Median age of cases was ten years (interquartile range 6–15), 54% were male and median percentage predicted forced expiratory volume in one second was 94% (interquartile range 79–104). The majority (71%) of children were managed in the community during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antiviral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had lower lung function and reduced body mass index Z-scores. One child died six weeks after testing positive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease. Conclusions: SARS-CoV-2 infection in children with CF is usually associated with a mild illness in those who do not have pre-existing severe lung disease.
KW - COVID-19
KW - Children
KW - Cystic fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85099512427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099512427&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2020.11.021
DO - 10.1016/j.jcf.2020.11.021
M3 - Article
C2 - 33309057
AN - SCOPUS:85099512427
SN - 1569-1993
VL - 20
SP - 25
EP - 30
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 1
ER -